^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
Published date:
07/12/2022
Excerpt:
KRASG12C inhibitor-naïve patients with KRAS p.G12C-mutated NSCLC were treated in 12 dose exploration cohorts at varying doses of sotorasib (120-960mg QD) in combination with either intravenous Atezo 1200mg or Pembro 200mg….Across all 12 cohorts, confirmed response was observed in 17 of 58 patients (29%; range, 0-67). Among the 17 responders, median duration of response was 17.9 months (range: 1.5+, 23.4). For all 58 patients across cohorts, median OS was 15.7 months (95% CI: 9.8, 17.8).
